Nuclear Medicine and Neurooncology (NMN)
@nmnsymposium.bsky.social
Advancing Nuclear Medicine and Neurooncology through research and education. Join the #NMN2025 Symposium on May 09/10th 2025 in Vienna, Austria.
nmn-society.org
nmn-society.org
Pinned
🚨 Apply now! The "NMN Clinical tRiaLisT Fellowship" offers training and hands-on experience in clinical trial development for theranostic treatments in CNS tumors: www.nmn-society.org/clinical-tri...!
@eanoassociation.bsky.social @neuroonc.bsky.social @eortc.org
@eanoassociation.bsky.social @neuroonc.bsky.social @eortc.org
Reposted by Nuclear Medicine and Neurooncology (NMN)
Outstanding oral presentation at #EANO2025 in Prague, now published in #NeuroOncology: the Multicenter Randomized Phase II Study of R-MPV-A #Chemoimmunotherapy With or Without Low-Dose Whole-Brain #Radiotherapy for Newly-Diagnosed Primary... by Antonio Omuro & colleagues.
👉 doi.org/10.1093/neuo...
👉 doi.org/10.1093/neuo...
November 12, 2025 at 10:58 AM
Outstanding oral presentation at #EANO2025 in Prague, now published in #NeuroOncology: the Multicenter Randomized Phase II Study of R-MPV-A #Chemoimmunotherapy With or Without Low-Dose Whole-Brain #Radiotherapy for Newly-Diagnosed Primary... by Antonio Omuro & colleagues.
👉 doi.org/10.1093/neuo...
👉 doi.org/10.1093/neuo...
Reposted by Nuclear Medicine and Neurooncology (NMN)
🧠 Thank you for joining us! The #EANOYoungsters #JournalClub on “Lighting up PET imaging in IDH mutant gliomas” brought together colleagues worldwide for a vibrant exchange on cutting-edge #NeuroOncology research.
▶️ Missed it? The recording will be available soon:
www.youtube.com/@eano_associ...
▶️ Missed it? The recording will be available soon:
www.youtube.com/@eano_associ...
November 13, 2025 at 7:49 AM
🧠 Thank you for joining us! The #EANOYoungsters #JournalClub on “Lighting up PET imaging in IDH mutant gliomas” brought together colleagues worldwide for a vibrant exchange on cutting-edge #NeuroOncology research.
▶️ Missed it? The recording will be available soon:
www.youtube.com/@eano_associ...
▶️ Missed it? The recording will be available soon:
www.youtube.com/@eano_associ...
Reposted by Nuclear Medicine and Neurooncology (NMN)
✏️Our Editorial - International funding for cancer care: a shared responsibility
thelancet.com/journals/lan...
🎧Listen to our podcast: Deputy Editor Ali Landman speaks with Matthias Preusser on the phase 2 TUXEDO-3 trial in patients with brain metastases
thelancet.com/multimedia/p...
thelancet.com/journals/lan...
🎧Listen to our podcast: Deputy Editor Ali Landman speaks with Matthias Preusser on the phase 2 TUXEDO-3 trial in patients with brain metastases
thelancet.com/multimedia/p...
October 28, 2025 at 10:46 AM
✏️Our Editorial - International funding for cancer care: a shared responsibility
thelancet.com/journals/lan...
🎧Listen to our podcast: Deputy Editor Ali Landman speaks with Matthias Preusser on the phase 2 TUXEDO-3 trial in patients with brain metastases
thelancet.com/multimedia/p...
thelancet.com/journals/lan...
🎧Listen to our podcast: Deputy Editor Ali Landman speaks with Matthias Preusser on the phase 2 TUXEDO-3 trial in patients with brain metastases
thelancet.com/multimedia/p...
🎧 Check out the The Lancet Oncology podcast discussing the back-to-back publications of the TUXEDO-3 trial: www.thelancet.com/doi/story/10...
👉 Cohort 1 (breast cancer) paper:
authors.elsevier.com/a/1m007_XRRT...
👉Cohort 2 (lung cancer) paper: authors.elsevier.com/a/1m0075EIIg...
👉 Cohort 1 (breast cancer) paper:
authors.elsevier.com/a/1m007_XRRT...
👉Cohort 2 (lung cancer) paper: authors.elsevier.com/a/1m0075EIIg...
October 28, 2025 at 8:19 AM
🎧 Check out the The Lancet Oncology podcast discussing the back-to-back publications of the TUXEDO-3 trial: www.thelancet.com/doi/story/10...
👉 Cohort 1 (breast cancer) paper:
authors.elsevier.com/a/1m007_XRRT...
👉Cohort 2 (lung cancer) paper: authors.elsevier.com/a/1m0075EIIg...
👉 Cohort 1 (breast cancer) paper:
authors.elsevier.com/a/1m007_XRRT...
👉Cohort 2 (lung cancer) paper: authors.elsevier.com/a/1m0075EIIg...
Reposted by Nuclear Medicine and Neurooncology (NMN)
Two studies led by former #EANO President Matthias Preusser demonstrate the activity of HER3-DXd in patients with brain metastases from breast and lung cancer.
Just published back-to-back in @thelancetoncol.bsky.social:
👉 breast cancer: bit.ly/4oEN1T2
👉 lung cancer: bit.ly/3LarqUf
#TUXEDO3
Just published back-to-back in @thelancetoncol.bsky.social:
👉 breast cancer: bit.ly/4oEN1T2
👉 lung cancer: bit.ly/3LarqUf
#TUXEDO3
October 27, 2025 at 11:45 PM
Two studies led by former #EANO President Matthias Preusser demonstrate the activity of HER3-DXd in patients with brain metastases from breast and lung cancer.
Just published back-to-back in @thelancetoncol.bsky.social:
👉 breast cancer: bit.ly/4oEN1T2
👉 lung cancer: bit.ly/3LarqUf
#TUXEDO3
Just published back-to-back in @thelancetoncol.bsky.social:
👉 breast cancer: bit.ly/4oEN1T2
👉 lung cancer: bit.ly/3LarqUf
#TUXEDO3
🔥 The program for #NMN2026 is online: www.nmn-society.org/program/! Check out the outstanding speaker panel and cutting edge topics on PET imaging and theranostics of primary and secondary CNS tumors.
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
October 23, 2025 at 12:50 PM
🔥 The program for #NMN2026 is online: www.nmn-society.org/program/! Check out the outstanding speaker panel and cutting edge topics on PET imaging and theranostics of primary and secondary CNS tumors.
☢️ Insightful perspective article by William Chen and David Raleigh on the LUMEN-1 trial in The Journal of Nuclear Medicine :
jnm.snmjournals.org/content/earl...
@eortc.org
jnm.snmjournals.org/content/earl...
@eortc.org
October 19, 2025 at 9:44 AM
☢️ Insightful perspective article by William Chen and David Raleigh on the LUMEN-1 trial in The Journal of Nuclear Medicine :
jnm.snmjournals.org/content/earl...
@eortc.org
jnm.snmjournals.org/content/earl...
@eortc.org
🔥 Check out the brand new editorial featuring the two randomized sister trials from Europe and the US on theranostics for meningioma in the Journal of Nuclear Medicine: jnm.snmjournals.org/content/earl...
@eortc.org
@eortc.org
October 18, 2025 at 4:04 PM
🔥 Check out the brand new editorial featuring the two randomized sister trials from Europe and the US on theranostics for meningioma in the Journal of Nuclear Medicine: jnm.snmjournals.org/content/earl...
@eortc.org
@eortc.org
🧠 💫 Amino acid PET imaging and its potential role for supramarginal resection being discussed at #EANO2025.
@eanoassociation.bsky.social
@eanoassociation.bsky.social
October 18, 2025 at 12:53 PM
🧠 💫 Amino acid PET imaging and its potential role for supramarginal resection being discussed at #EANO2025.
@eanoassociation.bsky.social
@eanoassociation.bsky.social
🤩 Emeline Tabouret presenting the randomized phase II LUMEN-1 (EORTC-2334-BTG) trial on Lu-DOTATATE in recurrent meningioma at #EANO2025 - 🚀 accrual going very well!
@eortc.org @eanoassociation.bsky.social
@eortc.org @eanoassociation.bsky.social
October 18, 2025 at 7:07 AM
🤩 Emeline Tabouret presenting the randomized phase II LUMEN-1 (EORTC-2334-BTG) trial on Lu-DOTATATE in recurrent meningioma at #EANO2025 - 🚀 accrual going very well!
@eortc.org @eanoassociation.bsky.social
@eortc.org @eanoassociation.bsky.social
🌍 Strengthening medical imaging capacity will save lives: spotlight on the recent @who.int landmark resolution on strengthening medical imaging capacity worldwide.
www.nature.com/articles/s41...
@natureportfolio.nature.com
www.nature.com/articles/s41...
@natureportfolio.nature.com
October 14, 2025 at 10:13 AM
🌍 Strengthening medical imaging capacity will save lives: spotlight on the recent @who.int landmark resolution on strengthening medical imaging capacity worldwide.
www.nature.com/articles/s41...
@natureportfolio.nature.com
www.nature.com/articles/s41...
@natureportfolio.nature.com
🤩 🤝 Looking forward to welcoming the Editor-in-Chief of The Lancet Oncology David Collingridge at #NMN2026: www.nmn-society.org!
@thelancetoncol.bsky.social
www.thelancet.com/journals/lan...
@thelancetoncol.bsky.social
www.thelancet.com/journals/lan...
October 14, 2025 at 9:29 AM
🤩 🤝 Looking forward to welcoming the Editor-in-Chief of The Lancet Oncology David Collingridge at #NMN2026: www.nmn-society.org!
@thelancetoncol.bsky.social
www.thelancet.com/journals/lan...
@thelancetoncol.bsky.social
www.thelancet.com/journals/lan...
🤩 Proud to announce that COGNO is endorsing the #NMN2026 Symposium to be held on May 07/08th 2026 in Vienna: www.nmn-society.org! 🌍 Looking forward to collaborating with our colleagues from Australia on molecular imaging and theranostics for brain tumors! 💫
cogno.org.au
@nathaliealbert.bsky.social
cogno.org.au
@nathaliealbert.bsky.social
October 10, 2025 at 2:27 PM
🤩 Proud to announce that COGNO is endorsing the #NMN2026 Symposium to be held on May 07/08th 2026 in Vienna: www.nmn-society.org! 🌍 Looking forward to collaborating with our colleagues from Australia on molecular imaging and theranostics for brain tumors! 💫
cogno.org.au
@nathaliealbert.bsky.social
cogno.org.au
@nathaliealbert.bsky.social
Reposted by Nuclear Medicine and Neurooncology (NMN)
How to disconnect therapy-resistant tumor networks in glioblastoma?
In our paper, online @Cancer Discovery, we built an anti-tumor microtube (TM) screening pipeline and found that Protein Kinase C activators disrupt TMs, silence Ca²⁺ “pacemakers” and boost radiotherapy.
doi.org/10.1158/2159...
In our paper, online @Cancer Discovery, we built an anti-tumor microtube (TM) screening pipeline and found that Protein Kinase C activators disrupt TMs, silence Ca²⁺ “pacemakers” and boost radiotherapy.
doi.org/10.1158/2159...
October 9, 2025 at 8:52 PM
How to disconnect therapy-resistant tumor networks in glioblastoma?
In our paper, online @Cancer Discovery, we built an anti-tumor microtube (TM) screening pipeline and found that Protein Kinase C activators disrupt TMs, silence Ca²⁺ “pacemakers” and boost radiotherapy.
doi.org/10.1158/2159...
In our paper, online @Cancer Discovery, we built an anti-tumor microtube (TM) screening pipeline and found that Protein Kinase C activators disrupt TMs, silence Ca²⁺ “pacemakers” and boost radiotherapy.
doi.org/10.1158/2159...
💫 New publication in EJNMMI: "Revealing the hidden: A systematic review and meta-analysis of FAPI-based tracers imaging for brain metastatic lesions."
link.springer.com/article/10.1...
link.springer.com/article/10.1...
October 8, 2025 at 8:59 AM
💫 New publication in EJNMMI: "Revealing the hidden: A systematic review and meta-analysis of FAPI-based tracers imaging for brain metastatic lesions."
link.springer.com/article/10.1...
link.springer.com/article/10.1...
💫 Check out the new article in the inaugural issue of the new EANM Journal:
EANM insights on PET-based response assessment in neuro-oncology: things are moving forward!
doi.org/10.1016/j.ea...
@eanm.org
EANM insights on PET-based response assessment in neuro-oncology: things are moving forward!
doi.org/10.1016/j.ea...
@eanm.org
September 24, 2025 at 7:09 AM
💫 Check out the new article in the inaugural issue of the new EANM Journal:
EANM insights on PET-based response assessment in neuro-oncology: things are moving forward!
doi.org/10.1016/j.ea...
@eanm.org
EANM insights on PET-based response assessment in neuro-oncology: things are moving forward!
doi.org/10.1016/j.ea...
@eanm.org
Reposted by Nuclear Medicine and Neurooncology (NMN)
We’re thrilled to see so many high-quality submissions coming in for our journals! 🎉
Explore the latest publications and the editorials written by our EANM Board and Editors-in-Chief:
👉 The EANM Journal: sciencedirect.com/journal/the-...
👉 EANM Innovation: sciencedirect.com/journal/eanm...
Explore the latest publications and the editorials written by our EANM Board and Editors-in-Chief:
👉 The EANM Journal: sciencedirect.com/journal/the-...
👉 EANM Innovation: sciencedirect.com/journal/eanm...
September 24, 2025 at 6:41 AM
We’re thrilled to see so many high-quality submissions coming in for our journals! 🎉
Explore the latest publications and the editorials written by our EANM Board and Editors-in-Chief:
👉 The EANM Journal: sciencedirect.com/journal/the-...
👉 EANM Innovation: sciencedirect.com/journal/eanm...
Explore the latest publications and the editorials written by our EANM Board and Editors-in-Chief:
👉 The EANM Journal: sciencedirect.com/journal/the-...
👉 EANM Innovation: sciencedirect.com/journal/eanm...
🚨New paper in EJNMMI: [177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data.
link.springer.com/article/10.1...
link.springer.com/article/10.1...
[177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data - European Journal of Nuclear Medicine and Molecular Imaging
Purpose This study aimed to reveal the factors affecting the therapeutic response of refractory meningiomas treated with [177Lu]Lu-DOTATATE and to collect initial tumor absorbed doses. Methods Patient...
link.springer.com
September 22, 2025 at 4:09 PM
🚨New paper in EJNMMI: [177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data.
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Reposted by Nuclear Medicine and Neurooncology (NMN)
Who’s ready for 2025 WFNOS/SNO Annual meeting in Honolulu?!
Register by Sept 19 to get early bird pricing and join colleagues from around the world in advancing #neurooncology.
soc-neuro-onc.org/SNO2025
Register by Sept 19 to get early bird pricing and join colleagues from around the world in advancing #neurooncology.
soc-neuro-onc.org/SNO2025
September 5, 2025 at 3:38 PM
Who’s ready for 2025 WFNOS/SNO Annual meeting in Honolulu?!
Register by Sept 19 to get early bird pricing and join colleagues from around the world in advancing #neurooncology.
soc-neuro-onc.org/SNO2025
Register by Sept 19 to get early bird pricing and join colleagues from around the world in advancing #neurooncology.
soc-neuro-onc.org/SNO2025
🧠 EANS-EANO Guidelines on the extent of resection in gliomas.
academic.oup.com/neuro-oncolo...
@eanoassociation.bsky.social @neuroonc.bsky.social
academic.oup.com/neuro-oncolo...
@eanoassociation.bsky.social @neuroonc.bsky.social
EANS-EANO Guidelines on the extent of resection in gliomas
Abstract. Intense efforts are employed to optimize neurosurgical resection of gliomas in different clinical scenarios. However, the level of evidence emplo
academic.oup.com
September 17, 2025 at 3:47 PM
🧠 EANS-EANO Guidelines on the extent of resection in gliomas.
academic.oup.com/neuro-oncolo...
@eanoassociation.bsky.social @neuroonc.bsky.social
academic.oup.com/neuro-oncolo...
@eanoassociation.bsky.social @neuroonc.bsky.social
🚨 💫 Happy to share that that @eortc.org is a 🙌 collaboration partner for the #NMN2026 Symposium: www.nmn-society.org!
@nathaliealbert.bsky.social
@nathaliealbert.bsky.social
September 13, 2025 at 2:08 PM
🚨 💫 Happy to share that that @eortc.org is a 🙌 collaboration partner for the #NMN2026 Symposium: www.nmn-society.org!
@nathaliealbert.bsky.social
@nathaliealbert.bsky.social
🚨 New publication in Journal of Nuclear Medicine: Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET/CT and Histopathology in Patients with Suspected Intracranial Meningiomas.
jnm.snmjournals.org/content/earl...
jnm.snmjournals.org/content/earl...
Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET/CT and Histopathology in Patients with Suspected Intracranial Meningiomas
The aim of this retrospective study was to evaluate the correlation between findings from somatostatin receptor (SSTR) PET/CT and histopathology in patients with suspected intracranial meningiomas. Me...
jnm.snmjournals.org
September 12, 2025 at 12:42 PM
🚨 New publication in Journal of Nuclear Medicine: Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET/CT and Histopathology in Patients with Suspected Intracranial Meningiomas.
jnm.snmjournals.org/content/earl...
jnm.snmjournals.org/content/earl...
🌎 ☢️ 🩺 Implementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Implementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access
Radiotheranostics represent a cutting-edge advancement in the management of noncommunicable diseases, integrating diagnostic imaging with targeted rad…
www.sciencedirect.com
September 11, 2025 at 2:55 PM
🌎 ☢️ 🩺 Implementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
New publication in Nature Reviews Clinical Oncology: The molecular blueprint of targeted radionuclide therapy.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
The molecular blueprint of targeted radionuclide therapy - Nature Reviews Clinical Oncology
Targeted radionuclide therapy (TRT) is a therapeutic modality that combines the strengths of radiotherapy and systemic molecularly targeted therapy. Over the past few years, new TRT agents have been d...
www.nature.com
September 11, 2025 at 2:24 PM
New publication in Nature Reviews Clinical Oncology: The molecular blueprint of targeted radionuclide therapy.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Prognostic value of [18F]FET-PET in diffuse low-grade (grade 2) gliomas after the 2021 classification of CNS tumors.
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Prognostic value of [18F]FET-PET in diffuse low-grade (grade 2) gliomas after the 2021 classification of CNS tumors - European Journal of Nuclear Medicine and Molecular Imaging
Purpose Amino acid PET with [18F]-fluoroethylthyrosine ([18F]FET-PET) is frequently utilized in gliomas. Most studies on prognostication based on amino acid PET comprise mixed cohorts of brain tumors ...
link.springer.com
September 10, 2025 at 8:24 AM
Prognostic value of [18F]FET-PET in diffuse low-grade (grade 2) gliomas after the 2021 classification of CNS tumors.
link.springer.com/article/10.1...
link.springer.com/article/10.1...